Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of...
-
Upload
alyson-evans -
Category
Documents
-
view
215 -
download
0
Transcript of Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of...
![Page 1: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/1.jpg)
Neuromodulation – what the future brings…
Alon Y. Mogilner, MD, PhDAssociate Professor of NeurosurgeryDirector, Center for Neuromodulation
NYU Langone Medical Center
![Page 2: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/2.jpg)
Disclosures
• Medtronic neurological:– Consultant, fellowship/grant support
• St. Jude Medical:– Grant support, consultant
• Boston Scientific– Grant Support
![Page 3: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/3.jpg)
Neuromodulation – the past…
![Page 4: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/4.jpg)
Neuromodulation: Emerging Indications
• DBS: Currently FDA-approved for:– Movement Disorders (PD, ET, Dystonia)– Psychiatric Conditions (OCD)
• In clinical trials for:– Treatment-refractory depression– Chronic pain
• Other conditions:– Tourette’s syndrome– Brain injury states– Obesity– Cognitive/Memory Enhancement
![Page 5: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/5.jpg)
Psychiatric Indications
• OCD:• Approved under an FDA HDE (humanitarian device
exemption)• Few cases reported in the literature• Target: anterior limb of the internal capsule (ALIC)
![Page 6: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/6.jpg)
OCD demographics
• OCD affects approx 2-3% of the population• An estimated 4m people affected in the US• An estimated 20% of OCD patients suffer from
intractable or treatment resistant symptoms (Husted DS, 2004).
![Page 7: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/7.jpg)
OCD Pathophysiology
• The “ventral cognitive” component of the cortico-striato-thalamo-cortical (CSTC) circuit appears central to the pathophysiology of OCD
• This circuit projects from the anterior and lateral orbitofrontal cortex (OFC) through the putamen and regulates context-related operations and response inhibition (Dougherty DD, 2010)
![Page 8: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/8.jpg)
OCD Pathophysiology, cont’d
• The cortico-thalamic pathway (C-T), which is excitatory, lies within this circuit and runs from OFC to the thalamus to ALIC.
• It is balanced by an inhibitory pathway that runs from the OFC through the ventral striatum to the thalamus (C-S-T)
• OCD symptoms are believed to arise when the CST pathway does not appropriately inhibit the CT pathway (e.g., decreased CST or increased CT activity). (Shah DB, 2008)
![Page 9: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/9.jpg)
OCD Pathophysiology: CSTC Circuit
Bear et al, J Clin Neurosci 2010
![Page 10: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/10.jpg)
Anterior Capsulotomy
• Targets ALIC and underlying striatum• Disconnects PFC and DM thalamus• 3 year study n=35 reported 25 with
marked improvement, 10 with modimprovement, 5 with no change. Responders demonstrated reducedhypermetabolism in ACC, OFC, caudate(Liu, J Clin Neurosci 2008)
![Page 11: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/11.jpg)
First DBS OCD publication: Lancet 1999
Electrical stimulation in anterior limbs of internal capsules in patients with obsessive-compulsive disorder
Bart Nuttin, Paul Cosyns, Hilde Demeulemeester, Jan Gybels, Björn Meyerson
Chronic electrical stimulation instead of bilateral capsulotomy was done in four selected patients with long-standing treatment-resistant obsessive-compulsive disorder. In three of them beneficial effects were observed.
![Page 12: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/12.jpg)
ALIC Stimulation
• ALIC connects the PFC and thalamus
• Stimulation may disrupt over-active C-T pathway
• Active electrodes often involve nuc accumbens
• Typical settings
![Page 13: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/13.jpg)
DBS lead location: ALIC
![Page 14: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/14.jpg)
3 YR Data on DBS for OCD
• N=10 across 2 centers. Age 21-58 (6m/4f), presurgical YBOCS 32-38; 8/10 w/ depression. Not controlled/blinded
• One asymptomatic hemorrhage, one seizure and one infection. One later died from BRCA.
• DBS discontinued in 2 due to lack of efficacy (12 and 24m)• Mean YBOCS 22.3 at 36m• 4 of 8 defined as responders at 36m (> 35% reduction in
YBOCS), 6 out of 8 achieved > 25% reduction• 6 subjects able to return to work (vs 0 pre-op)• No domains of cognitive decline on f/u neuropsych
Greenberg, Neuropsychopharm 2006
![Page 15: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/15.jpg)
3-Yr DBS outcomes, contd
![Page 16: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/16.jpg)
Assessing Candidacy for OCD DBS
• Severe OCD meeting DSM criteria (e.g., YBOCS > 27)• At least 10 wks of a maximally tolerated dose of > 3
SSRIs and augmentation x 1m with at least 2 of the following: lithium, buspirone, clonazepam or neuroleptic
• At least 20h of behavioral therapy• Adequate compliance and dose levels• A treating psychiatrist able to follow peri- and post-
operatively
Dougherty et al, Am J Psych 2002
![Page 17: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/17.jpg)
Obsessive picking post-DBS
![Page 18: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/18.jpg)
Tourette’s Syndrome• Presence of motor and vocal tics, typically
beginning before age 18 and not secondary to another neurological condition
• Often comorbid ADHD and OCD (40-70%). Debated if OCD in TS is different than isolated OCD
• Prevalence between 1 – 30 out of 1000; 3x more common in males
• Frequent family history though genetics unclear• Typically wanes by end of adolescence but approx
25% still have continuation of tics in adulthood.
![Page 19: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/19.jpg)
Tourette’s Syndrome• Presence of motor and vocal tics, typically
beginning before age 18 and not secondary to another neurological condition
• Often comorbid ADHD and OCD (40-70%). Debated if OCD in TS is different than isolated OCD
• Prevalence between 1 – 30 out of 1000; 3x more common in males
• Frequent family history though genetics unclear• Typically wanes by end of adolescence but approx
25% still have continuation of tics in adulthood.
![Page 20: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/20.jpg)
DBS and Tourette’s
Optimal target not yet determined:Anterior limb of internal
capsuleCentromedian nucleus of
thalamusGlobus Pallidus interna
Approximately 100 cases thus far with promising but mixed results
![Page 21: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/21.jpg)
![Page 22: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/22.jpg)
Thalamic stim for TSAuthor Target N Effect Follow-
up
Vandewalle 1999;2003;2010
Medialthalamus
3 72-90% reduction 8-72m
Macunias 2007 Med thal 5 40% less motor; 20% more vocal tics
3m
Bajwa 2007 Med thal 1 66% reduction + improved OCD
24m
Ackermans 2011 Med thal 6 37% improvement 12m
Servello 2008 Ant/med thal 18 24-79% improvement 3-18m
Porta 2009 Med thal 15 YGTSS 76 to 36 24m
Adapted from Ackermans, World NS 2012
Most GPi and IC/NA data limited to single case reports except Martinez-Fernandez 2011 (3 pts,Gpi, 37% improvement at 18m and Servello 2009 (4 pts, IC/NA, 49-82% improvement at 26m)
![Page 23: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/23.jpg)
A learning experience…
![Page 24: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/24.jpg)
DBS for Depression: Clinical Trials
• Brodmann’s area 24/25 – BROADEN study (St. Jude Medical)– 18 sites– Approximately 200 patients– Randomized, double blinded trial
• VC/VS - RECLAIM study (Medtronic)– Randomized, double-blinded trial
![Page 25: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/25.jpg)
![Page 26: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/26.jpg)
Other indications
• Cognitive/Memory Enhancement:– Forniceal/hypothalamic stimulation
• Brain Injury States:– Medial thalamic stimulation
![Page 27: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/27.jpg)
Peripheral Stimulation for headache and craniofacial pain
• Goadsby (1997): Stimulation of greater occipital nerve (GON) in cats resulted in increased metabolic activity of the trigeminal nucleus caudalis and cervical dorsal horn3
• Weiner (1999): Peripheral neurostimulation for occipital neuralgia4
• Goadsby (2004): ONS for migraine headache5
3. Goadsby PJ, Knight YE, Hoskin KL. Stimulation of the greater occipital nerve increases metabolic activity in the trigeminal nucleus caudalis and cervical dorsal horn of the cat. Pain 1997; 73(1):23-8.4. Weiner RL, Reed KL. Peripheral neurostimulation for control of intractable occipital neuralgia. Neuromodulation 1999; 2(3):217-21.5. Matharu MS, Bartsch T, Ward N, Frackowiak RSJ, Weiner RL, Goadsby PJ. Central neuromodulation in chronic migraine patients with suboccipital stimulators: A PET study. Brain 2004;127:220-30.
![Page 28: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/28.jpg)
Peripheral Stimulation: headache and facial pain
• Most Common technique:– Occipital Nerve Stimulation
• Occipital stimulation• “BOTH” stimulation
• Other techniques:– Trigeminal branch stimulation
• Supraorbital• Supratrochlear• Auriculotemporal
![Page 29: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/29.jpg)
Procedure
![Page 30: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/30.jpg)
Results: Analysis of Indications
Diagnosis Number of
PatientsNumber of Successful Trials
Number of Permanent Systems still used at Last Follow-up
7.7: Headache attributed to Chiari Malformation type I
28 18 15
1.1 or 1.2: Migraine Headache with or without Aura
24 21 19
5.2.2: Chronic post-traumatic headache attributed to mild head injury
11 10 8
13.8: Occipital Neuralgia 8 7 7
5.7.2: Post-Craniotomy Headache 7 7 6
3.1.2: Chronic Cluster Headache 5 4 4
6.1.1: Headache attributed to ischemic stroke
5 3 1
13.7: Other terminal branch neuralgias 5 4 1
11.2.1: Cervicogenic Headache 4 3 3
4.7: Hemicrania Continua 1 1 1
7.4.4:Headache attributed to hypothalamic or pituitary hyper- or hyposecretion
1 1 0
![Page 31: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/31.jpg)
Neurostimulation for Migraine: Clinical Trials
• 3 to date, Boston Scientific, Medtronic, St. Jude• Most recent: St. Jude study
– Significant group differences for reduction in number of headache days, MIDAS, Zung PAD, VAS, quality of life and satisfaction at 12 weeks were observed (p< 0.05).
– In the Active and Control groups respectively, number of headache days (defined as a > 4 hours duration at moderate intensity) decreased by 7.3 and 4.3, total MIDAS scores improved by 64.6 and 20.4, MIDAS headache days improved by 22.5 and 3.4, PAD scores improved by 13.3 and 5.5, VAS scores decreased by 13.6 and 6.9, 37.1% and 17.3% of patients achieved a 30% reduction in VAS.
– In addition, 66.7% of patients in the Active group reported improved quality of life whereas only 17.2% of patients in the control group reported the same. For satisfaction, 51.4% of patients in the Active group reported being satisfied whereas only 19.2% in the Control group reported being satisfied.
– HOWEVER, primary endpoint (>50% pain reduction) not reached
![Page 32: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/32.jpg)
Hardware improvements
• “Closed-loop stimulation”– System senses abnormal activity and changes
output accordingly
• “Current steering”– Multiple contacts with current fractionalization
may allow finer tuning of stimulation with fewer side effects
![Page 33: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/33.jpg)
![Page 34: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/34.jpg)
![Page 35: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/35.jpg)
The future?
“The future ain’t what it used be…
![Page 36: Neuromodulation – what the future brings… Alon Y. Mogilner, MD, PhD Associate Professor of Neurosurgery Director, Center for Neuromodulation NYU Langone.](https://reader036.fdocuments.in/reader036/viewer/2022081516/56649ee55503460f94bf537c/html5/thumbnails/36.jpg)
Summary
• We are entering a “brave new world” of neuromodulation
• Future advances will entail:– Better understanding of pathophysiology– Improvements in technology– Clear evidence-based medicine documenting
clinical benefit…